| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Internal Medicine, Dartmouth Medical School, Hanover, NH.
Epidemiologic evidence has suggested a negative association between cigarette smoking and the risk of Parkinson's disease. Although many of the studies had limitations, in aggregate they suggest that smoking may actually be a protective exposure. Other lines of evidence support this view, especially animal data indicating a dopaminergic effect of smoking on the brain.
Address correspondence and reprint requests to Dr. Baron, Department of Internal Medicine, Dartmouth Medical School. Hanover, NH 03756.
Partially supported by the Milbank Memorial Fund (Milbank Scholar Program).
Accepted for publication March 8, 1986.
This article has been cited by other articles:
|
|
 |
|
  A. H.V. Schapira Etiology of Parkinson's disease Neurology, May 23, 2006; 66(10_suppl_4): S10 - S23. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Charlton Medicinal uses of tobacco in history J R Soc Med, June 1, 2004; 97(6): 292 - 296. [Full Text] [PDF]
|
|
|
|
 |
|
 X. D. Li and J. J. Buccafusco Effect of {beta}-Amyloid Peptide 1-42 on the Cytoprotective Action Mediated by {alpha}7 Nicotinic Acetylcholine Receptors in Growth Factor-Deprived Differentiated PC-12 Cells J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 670 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Van Den Eeden, C. M. Tanner, A. L. Bernstein, R. D. Fross, A. Leimpeter, D. A. Bloch, and L. M. Nelson Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity Am. J. Epidemiol., June 1, 2003; 157(11): 1015 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Klink, A. d. K. d'Exaerde, M. Zoli, and J.-P. Changeux Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic Nuclei J. Neurosci., March 1, 2001; 21(5): 1452 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Schneider, J. P. Tinker, M. Van Velson, F. Menzaghi, and G. K. Lloyd Nicotinic Acetylcholine Receptor Agonist SIB-1508Y Improves Cognitive Functioning in Chronic Low-Dose MPTP-Treated Monkeys J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 731 - 739. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Chavez-Noriega, J. H. Crona, M. S. Washburn, A. Urrutia, K. J. Elliott, and E. C. Johnson Pharmacological Characterization of Recombinant Human Neuronal Nicotinic Acetylcholine Receptors halpha 2beta 2, halpha 2beta 4, halpha 3beta 2, halpha 3beta 4, halpha 4beta 2, halpha 4beta 4 and halpha 7 Expressed in Xenopus Oocytes J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 346 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
F. Menzaghi, K. T. Whelan, V. B. Risbrough, T. S. Rao, and G. K. Lloyd Interactions between a Novel Cholinergic Ion Channel Agonist, SIB-1765F and L-DOPA in the Reserpine Model of Parkinson's Disease in Rats J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 393 - 401. [Abstract] [Full Text]
|
|
|
|
|
|
B. Buisson, M. Gopalakrishnan, S. P. Arneric, J. P. Sullivan, and D. Bertrand Human alpha 4beta 2 Neuronal Nicotinic Acetylcholine Receptor in HEK 293 Cells: A Patch-Clamp Study J. Neurosci., December 15, 1996; 16(24): 7880 - 7891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stern, E. Dulaney, S. B. Gruber, L. Golbe, M. Bergen, H. Hurtig, S. Gollomp, and P. Stolley The Epidemiology of Parkinson's Disease: A Case-Control Study of Young-Onset and Old-Onset Patients Arch Neurol, September 1, 1991; 48(9): 903 - 907. [Abstract] [PDF]
|
|
|
|
|
|
L. I. Golbe, R. A. Cody, and R. C. Duvoisin Parkinson's Disease and Smoking-Reply Arch Neurol, November 1, 1987; 44(11): 1111 - 1111. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
